Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL533056 | 0.85 | DBH (0.33) | ACHE | |
| SCHEMBL29760 | 0.83 | ACHE (0.36) | ACHE | |
| SCHEMBL944353 | 0.77 | ACHE (0.34) | ACHE | |
| SCHEMBL2285403 | 0.76 | TAS1R3 (0.31) | — | |
| SCHEMBL2285289 | 0.76 | CA2 (0.40) | — | |
| SCHEMBL4158740 | 0.74 | ACHE (0.41) | ACHE | |
| SCHEMBL2289413 | 0.73 | CA2 (0.41) | ACHE | |
| SCHEMBL5475365 | 0.73 | TDP1 (0.39) | ACHE | |
| SCHEMBL2286065 | 0.73 | KDM4E (0.31) | ACHE | |
| SCHEMBL15390519 | 0.72 | CYP11B1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110319426-A1 | Substituted Isoindoles | ASTRAZENECA AB (SE) | 2011-12-29 | — | — | US | claimed |
| EP-2367814-A1 | NEW COMPOUNDS 578 | AstraZeneca AB (SE) | 2011-09-28 | — | — | EP | claimed |
| US-20100125082-A1 | NEW COMPOUNDS 578 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | claimed |
| WO-2010056196-A1 | NEW COMPOUNDS 578 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | WO | claimed |
| US-20130310358-A1 | PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-11-21 | — | — | US | disclosed |
| US-20110319426-A1 | Substituted Isoindoles | ASTRAZENECA AB (SE) | 2011-12-29 | — | — | US | disclosed |
| US-8030500-B2 | Substituted isoindoles for the treatment and/or prevention of Aβ- related pathologies | ASTRAZENECA AB (SE) | 2011-10-04 | — | — | US | disclosed |
| EP-2367814-A1 | NEW COMPOUNDS 578 | AstraZeneca AB (SE) | 2011-09-28 | — | — | EP | disclosed |
| US-7989394-B2 | Substituted 1-(azolin-2-yl)-amino-2-aryl-1-hetaryl-ethane compounds | BASF SE (DE) | 2011-08-02 | — | — | US | disclosed |
| US-20100125082-A1 | NEW COMPOUNDS 578 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | US | disclosed |
| WO-2010056196-A1 | NEW COMPOUNDS 578 | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | WO | disclosed |
| US-20090131256-A1 | Substituted 1-(azolin-2-yl)-amino-2-aryl-1-hetaryl-ethane Compounds | BASF SE (DE) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125082-A1 | NEW COMPOUNDS 578 | PSEN1, PSEN2, BACE1 | ACHE 132/4885 |
| US-20130310358-A1 | PYRIMIDINE COMPOUNDS AS DELTA OPIOID RECEPTOR MODULATORS | OPRD1, OPRK1, OPRM1 | ACHE 707/4885 |
| US-20110319426-A1 | Substituted Isoindoles | PSEN2, PSEN1, SNCA | ACHE 190/4885 |
| US-20090131256-A1 | Substituted 1-(azolin-2-yl)-amino-2-aryl-1-hetaryl-ethane Compounds | AAAS, AIPL1, ATXN2 | ACHE 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.